$267 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 41 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EOCWU | ELLIOTT OPPORTUNITY II CORP | $19,750,000 | +0.8% | 2,000,000 | 0.0% | 7.40% | -12.7% | |
| IMTX | IMMATICS NV | $6,974,000 | +14.8% | 697,431 | 0.0% | 2.61% | -0.5% | |
| TXN | TEXAS INSTRUMENTS INC | $4,953,000 | +0.7% | 32,000 | 0.0% | 1.86% | -12.7% | |
| VT | VANGUARD TOT WORLD STK ETFetfs | $2,334,000 | -7.6% | 29,585 | 0.0% | 0.88% | -19.9% | |
| BOND | PIMCO ACTIVE BOND EXCHANGE-T | $1,391,000 | -5.8% | 15,502 | 0.0% | 0.52% | -18.5% | |
| CDAK | CODIAK BIOSCIENCES INC | $662,000 | -72.9% | 847,108 | 0.0% | 0.25% | -76.5% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $129,000 | +4.0% | 245,678 | 0.0% | 0.05% | -11.1% | |
| TFFP | TFF PHARMACEUTICALS INC | $90,000 | -28.0% | 22,066 | 0.0% | 0.03% | -37.0% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $86,000 | +30.3% | 35,714 | 0.0% | 0.03% | +10.3% | |
| POR | PORTLAND GENERAL ELECTRIC CO | $5,000 | -16.7% | 118 | 0.0% | 0.00% | -33.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4/A | 2024-05-14 |
| 4 | 2024-05-01 |
| 3 | 2024-04-30 |
| 13F-HR | 2024-04-30 |
| 144 | 2024-04-29 |
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-04 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.